Literature DB >> 9157575

A common thrombomodulin amino acid dimorphism is associated with myocardial infarction.

L Norlund1, J Holm, B Zöller, A K Ohlin.   

Abstract

Endothelial dysfunction and haemostatic imbalance are believed to be important aetiological factors in the development of acute coronary syndromes. Thrombomodulin (TM) is an integral membrane protein crucial for normal endothelial function and activation of the protein C anticoagulant pathway. We have investigated the importance of a common C/T dimorphism in the TM gene (nucleotide 1418) for development of premature myocardial infarction (MI). The C/T dimorphism predicts an Ala455 to Val replacement in the sixth EGF-like domain of TM. The dimorphism was investigated in 97 MI survivors and 159 healthy controls. The C allele was significantly more frequent among patients than controls (p = 0.035). The allele frequency for the C allele was 0.82 in the patients and 0.72 in the control group. The plasma concentration of TM was investigated among healthy controls but was not related to the C/T dimorphism. In conclusion, the association of the C allele with premature MI, suggests that the TM gene and the C/T dimorphism may be aetiological factors involved in the pathogenesis of MI. Possibly, the Ala455 to Val replacement may affect the function of the TM molecule and the activation of the protein C anticoagulant pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9157575

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  Variants associated with common disease are not unusually differentiated in frequency across populations.

Authors:  Kirk E Lohmueller; Matthew M Mauney; David Reich; John M Braverman
Journal:  Am J Hum Genet       Date:  2005-11-16       Impact factor: 11.025

Review 3.  Genetics and pulmonary medicine. 4. Pulmonary embolism.

Authors:  M Laffan
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

4.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.

Authors:  H Weiler-Guettler; P D Christie; D L Beeler; A M Healy; W W Hancock; H Rayburn; J M Edelberg; R D Rosenberg
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 5.  Acute lung injury and the coagulation pathway: Potential role of gene polymorphisms in the protein C and fibrinolytic pathways.

Authors:  Anil Sapru; Joseph L Wiemels; John S Witte; Lorraine B Ware; Michael A Matthay
Journal:  Intensive Care Med       Date:  2006-06-13       Impact factor: 17.440

6.  Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.

Authors:  Andrew Srisuwananukorn; Rasha Raslan; Xu Zhang; Binal N Shah; Jin Han; Michel Gowhari; Robert E Molokie; Victor R Gordeuk; Santosh L Saraf
Journal:  Blood Adv       Date:  2020-05-12

Review 7.  Thrombophilia, polymorphisms, and vascular disease.

Authors:  T C Sykes; C Fegan; D Mosquera
Journal:  Mol Pathol       Date:  2000-12

8.  Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion.

Authors:  Jingying Wang; Ji Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

9.  Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.

Authors:  Abrar Ahmad; Kristina Sundquist; Bengt Zöller; Peter J Svensson; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

10.  Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction.

Authors:  Joshua W Knowles; Huijan Wang; Haruka Itakura; Audrey Southwick; Richard M Myers; Carlos Iribarren; Stephen P Fortmann; Alan S Go; Thomas Quertermous; Mark A Hlatky
Journal:  Am Heart J       Date:  2007-12       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.